Diligence memo · auto-generated · as of July 2, 2026
Allelica, Inc.
Allelica, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Allelica, Inc. operates in Biotechnology, based in ROME.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Allelica, Inc. has raised $1.7M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.7M on 2021-03-05.
Most recent recorded round closed around 2021-03-05.
Valuation (modeled)modeled
Provath models Allelica, Inc. at approximately $51M (range $1.2M–$336M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.80× the median modeled value of Seed Biotechnology companies in 2019–2021 (186 peers) — value vs value, same stage and era. Within the normal band (80% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 5.3 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 25% of Biotechnology peers (4293 compared).
Modeled value ranks above 46% of those peers.
Closest niche peers: Novo Biosciences, Inc., Entac Medical, Inc., ReGelTec, Inc., Korro Bio, Inc., TamuroBio Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.